The round included a strategic investment from pharma giant Gilead Sciences to expand their partnership for decentralized and hybrid trials.
Decentralized clinical trial startup Curebase raises $40M
The round included a strategic investment from pharma giant Gilead Sciences to expand their partnership for decentralized and hybrid trials.
